[ad_1]
[앵커]
Pfizer’s COVID-19 prevention vaccine is officially licensed in Korea. It is second only to AstraZeneca, and the subject of the vaccination is over 16 years old. However, young people are not getting the vaccine right away, but reporter Lee Hyung-won reported why. Pfizer’s vaccine has been approved for the second time in Korea after AstraZeneca. With 95% of the preventive effect, there were few serious adverse reactions such as ‘anaphylaxis’, so it was concluded that vaccination was not far-fetched. Subjects eligible for vaccination were determined to be 16 years of age or older as a result of the two previous visits. The main benefit was that the Pfizer clinical trial was designed for subjects over 16 years of age, confirming its safety and preventive effects. Furthermore, the immune response of adolescents in this age group is no different than that of adults. The approval of those over 16 years of age in several countries such as the United States, Europe and Japan was also taken into account. However, it does not mean that young people will be vaccinated immediately. This is because home vaccination targets are limited to adults over 18 years of age. Whether the final vaccination goal will be changed is decided in the deliberation of the Vaccination Specialists Committee to be held in the future. Storage conditions were minus 90-60 degrees and up to 6 months as requested by Pfizer, unlike the content of the US FDA approval. The license for this item is for a vaccine purchased individually with Pfizer, and the quantity from Pfizer through ‘CoVax’ is specially imported and vaccination has already been done. YTN Hyungwon Lee[[email protected]]is. ※ ‘Your report becomes news’ YTN is waiting for your valuable report.
[카카오톡] Search YTN to add a channel [전화] 02-398-8585 [메일] [email protected] [온라인 제보] www.ytn.co.kr